Trastuzumab Completed Phase 3 Trials for Malignancies Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02721641A Continuation Study of Trastuzumab (Herceptin) in Participants With Metastatic or Locally Advanced Cancer
NCT00968968Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone